Treatment | Hospital category | % of patients treated according to guidelines | OR | 95% CI | |||
---|---|---|---|---|---|---|---|
 |  | ‘90-‘95 | ‘96-‘01 | ‘02-‘07 | ‘08-‘10 |  |  |
Complete breast conserving treatment. N = 22453 | Controls | 95.6 | 92.3 | 93.4 | 95.8 | 1.00 | Reference |
Inclusion criteria: Stage I-IIIA | North High IP | 97.8 | 97.1 | 97.8 | 98.3 | 2.68* | 2.08-3.45 |
Exclusion criterium: Breast amputation after BCS | North Low IP | 95.4 | 96.3 | 96.7 | 97.1 | 1.77* | 1.43-2.17 |
 | Rotterdam High IP | 93.0 | 88.9 | 91.9 | 96.7 | 0.77* | 0.64-0.92 |
 | Rotterdam Low IP | 94.6 | 89.6 | 91.7 | 95.0 | 0.72* | 0.60-0.85 |
Introduction of the SNB. N = 25612 | Controls | 0 | 33.9 | 93.6 | 98.3 | 1.00 | Reference |
Inclusion criteria: cT1-2, cN0, cM0, BCS | North high IP | 0 | 16.2 | 93.9 | 98.8 | 0.68* | 0.55-0.84 |
 | North low IP | 0 | 20.9 | 93.2 | 98.2 | 0.59* | 0.50-0.70 |
Rotterdam high IP | 0 | 19.1 | 89.0 | 98.8 | 0.46* | 0.38-0.55 | |
Rotterdam low IP | 0 | 14.8 | 92.1 | 96.9 | 0.48* | 0.40-0.57 | |
Radiotherapy after BCS for DCIS. N = 2414 | Controls | 16.1 | 31.7 | 76.8 | 85.2 | 1.00 | Reference |
Inclusion criteria: DCIS, BCS | North high IP | 50.0 | 49.0 | 74.8 | 84.9 | 1.24 | 0.88-1.74 |
 | North low IP | 57.1 | 43.7 | 72.5 | 81.7 | 1.13 | 0.84-1.52 |
Rotterdam high IP | 33.3 | 48.9 | 72.0 | 79.8 | 1.08 | 0.79-1.49 | |
Rotterdam low IP | 27.6 | 50.4 | 74.1 | 83.3 | 1.27 | 0.93-1.73 | |
Adjuvant radiotherapy locally advanced breast cancer N = 1511 | Controls | 64.6 | 67.3 | 64.6 | 69.1 | 1.00 | Reference |
Inclusion criteria: cT3,anyN,M0 and any T,N2-3,M0 + amputation | North high IP | 53.5 | 54.4 | 53.5 | 68.3 | 0.75 | 0.51-1.10 |
 | North low IP | 46.2 | 62.5 | 46.2 | 53.2 | 0.56* | 0.39-0.80 |
Rotterdam high IP | 39.2 | 34.2 | 39.2 | 61.5 | 0.40* | 0.29-0.55 | |
Rotterdam low IP | 29.7 | 35.9 | 29.7 | 68.6 | 0.36* | 0.25-0.52 | |
Adjuvant chemotherapy early stage breast cancer. N = 9511 | Controls | 51.3 | 73.1 | 85.1 | 91.9 | 1.00 | Reference |
Inclusion criteria: pT1-2 M0/X, surgery age < 60 | North high IP | 62.3 | 69.7 | 90.4 | 93.0 | 1.24 | 1.00-1.54 |
 | North low IP | 52.8 | 70.6 | 91.4 | 91.3 | 1.29* | 1.07-1.54 |
 | Rotterdam high IP | 60.2 | 72.3 | 88.0 | 95.6 | 1.50* | 1.26-1.81 |
Rotterdam low IP | 55.3 | 67.2 | 90.1 | 96.0 | 1.22* | 1.01-1.46 | |
Neo-adjuvant chemotherapy T4/M0 breast cancer. N = 1484 | Controls | 5.1 | 27.4 | 34.5 | 61.9 | 1.00 | Reference |
Inclusion criteria: cT4NxM0, surgery | North high IP | 11.2 | 25.0 | 56.0 | 65.3 | 1.24 | 0.73-2.09 |
 | North low IP | 4.8 | 22.8 | 57.8 | 44.0 | 1.57* | 1.00-2.47 |
 | Rotterdam high IP | 6.7 | 28.0 | 55.0 | 51.9 | 2.67* | 1.74-4.07 |
Rotterdam low IP | 5.3 | 29.2 | 54.8 | 61.5 | 2.02* | 1.32-3.08 |